B cell maturation antigen (BCMA) is a member of tumor necrosis factor receptor superfamily which pays critical role in regulating B cell proliferation and survival.
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion
- Market and Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 Drugs
- Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
B cell maturation antigen (BCMA) is a member of tumor necrosis factor receptor superfamily which pays critical role in regulating B cell proliferation and survival. Studies have shown that BCMA is preferentially expressed in in multiple myeloma cells and plays a key role in their survival, thus making it potential target for cancer therapy. At present, two BCMA targeted drugs have entered the market. Belantamab mafodotin (Blenrep) developed by GlaxoSmithkline was the first BCMA targeted drug approved for patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies. Later, Abecma developed by Bristol Myers Squibb entered the market was approved for the management of multiple myeloma. In short span of approval, these drugs have shown robust response in the global market which suggests the promising future of BCMA targeted therapy in the management of cancer.
BCMA as therapeutic target is gaining interest among the pharmaceuticlal companies which has led to development of robust clinical pipeline of drugs which are expected to enter the market in forthcoming years. Teclistamab developed by Janssen Pharmaceutical is an off-the-shelf, T-Cell redirecting, bispecific antibody targeting both BCMA and CD3 receptors. FDA and EMA have granted breakthrough therapy designation and PRIME designation respectively to the drug on the basis of encouraging response in phase-II/III clinical trial. Apart from this, recent study also demonstrated that the subcutaneous combination of Teclistamab and and daratumumab (Darzalex) produced promising preliminary efficacy and favorable tolerability in heavily pretreated patients with relapsed or refractory multiple myeloma. In 2022, Janssen Pharmaceutical has submitted marketing authorization application to US FDA as well EMA, and it is expected to gain approval by end of 2022.
Apart from this, Poseida Therapeutics also reported interim results from phase-I/II clinical trial of P-BCMA-101 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The results showed that P-BCMA-101, a non-viral transposon-based autologous CAR-T, was well tolerated and demonstrated strong anti-tumor activity in advanced, late line R/R MM patients. The other potential BCMA targeted drug in trials includes Allo715, CT053, HPN217, PHE885, AMG420, and others.
The pharmaceutical companies in the global market are actively indulging in collaboration or partnerships to increase the investment in this segment. In 2021, Springworks Therapeutics announced that the company has entered into a clinical trial collaboration agreement with Seagen to evaluate nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in combination with SEA-BCMA, Seagen’s investigational monoclonal antibody targeting B-cell maturation agent (BCMA), in patients with relapsed or refractory multiple myeloma. Apart from this, Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics have entered into an agreement pursuant to which Sana obtained from IASO Bio and Innovent non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct for use in certain in vivo gene therapy and ex vivo hypoimmune cell therapy applications.
The global BCMA targeted therapy market is estimated to surpass US$ 4 Billion by 2028. The high growth rates in the market are mainly attributed to increase in geriatric population and subsequent rise in prevalence of cancer. As per our analysis, forecast period will see rapid influx of BCMA targeted drugs in management of wide range of cancers which will further propel the growth of market. In addition, development of favorable reimbursement policies in regions including US and Europe is also propelling the growth in the market. Key players operating in the BCMA targeted therapies market are Celgene Corporation, Bluebird Bio, Poseida Therapeutics, Juno Therapeutics, and Eureka Therapeutics.
The report provides comprehensive analysis on the approved BCMA targeted drugs patent, price and sales insight 2020 Till 2028 and ongoing clinical trials assessment by status, phase, and region. The report also provides insights into future market opportunity and regional insights.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366